Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

Abstract Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, the drug lacks FDA approval in multiple myeloma thus far due to a potential safety signal in the overall patient population. Selinexor is a...

Full description

Bibliographic Details
Main Authors: Nina Nguyen, Sana Chaudhry, Tulasigeri M. Totiger, Robert Diaz, Evan Roberts, Skye Montoya, Gabriel Pardo, Alejandro Pardo, Jumana Afaghani, Maurizio Affer, Jacob Jahn, Terrence Bradley, Francesco Maura, Dickran Kazandjian, Daniel Bilbao, Jennifer Chapman, Ola Landgren, James Hoffman, Justin Taylor
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-022-00315-2

Internet

https://doi.org/10.1038/s41698-022-00315-2

Similar Items